Category

• Pipeline3

Organizations

• Bausch + Lomb64
• Eyes On Eyecare42
• Alcon, Inc.41
• American Optometric Association34
• Harrow26
• Glaukos25
• Regeneron21
• Aldeyra Therapeutics20
• Sight Sciences19
• American Academy Of Ophthalmology18

Tags

• AMD3
• Geographic Atrophy3
• FDA1
• Clinical Trials1
• Retina1

• Organizations: Cognition Therapeutics ✕

Clear all

Pipeline

First patient dosed in Cognition's MAGNIFY study for GA secondary to dry AMD

Orally-administered CT1812 has the potential to help patients retain visual acuity for a longer term.

Pipeline

Cognition Therapeutics’ IND for geographic atrophy earns FDA OK

A phase 2 study assessing CT1812 is planned for later this year. 

Pipeline

Cognition Therapeutics to report data favoring phase 2 trial for GA secondary to dry AMD

Findings support a phase 2 trial for CT1812, its lead candidate.